Johnson & Johnson's Ebola Vaccine Built On COVID-19 Tech Shows Durable Benefit
- Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (NYSE: JNJ) Ebola vaccine regimen showed a long-lasting immune response.
- The regimen, which uses Zabdeno (Ad26.ZEBOV) for one shot, and Mvabea (MVA-BN-Filo) for the next, 56 days later, spurred no safety concerns.
- J&J said that a booster shot could be administered two years after the initial vaccination, as it showed a strong immune response seven days later.
- “These peer-reviewed data support the prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect people at risk of Ebola, which is essential to our vision of preventing Ebola outbreaks before they can begin,” J&J CSO Paul Stoffels said in a statement.
- The EBOVAC-Salone study was conducted in Sierra Leone, a region heavily affected by the 2014-2016 West African Ebola outbreak.
- The study was conducted on healthy children between the ages of 1 and 17, split up into three cohorts.
- The most common side effect was injection site pain, the Lancet paper said.
- The Company said no treatment-related deaths were reported, and the antibody response was observed 21 days after the second dose in 98% of children.
- The vaccine regimen was approved in Europe in July 2020 and received prequalification from the WHO in April 2021. Earlier this year, outbreaks in Sierra Leone and Guinea caused J&J to announce the donation of 200,000 doses of the jab.
- Last month, J&J failed its first HIV vaccine trial based on the same vaccine technology used in the COVID-19 shot.
- Related Content: Johnson & Johnson Stops HIV Vaccine Trial In African Women.
- Price Action: JNJ stock is down 0.59% at $164.80 during the market session on the last check Tuesday.
- Image by Wilfried Pohnke from Pixabay
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs EbolaBiotech News Health Care General Best of Benzinga
